Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma
Kersten, Marie José; Driessen, Julia; Zijlstra, José M; Plattel, Wouter J; Morschhauser, Franck; Lugtenburg, Pieternella J; Brice, Pauline; Hutchings, Martin; Gastinne, Thomas; Liu, Roberto
Published in:
Haematologica

DOI:
10.3324/haematol.2019.243238

IMPORTANT NOTE: You are advised to consult the publisher’s version (publisher’s PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher’s PDF, also known as Version of record

Publication date:
2021

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Takedown policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRAVE study

Marie José Kersten,1,2* Julia Driessen,1* Josée M. Zijlstra,2,3 Wouter J. Plattel,1,4 Franck Morschhauser,5 Pieternelia J. Lugtenburg,6,7 Pauline Brice,3 Martin Hutchings,8 Thomas Gastinne,9 Roberto Liu,1 Coreline N. Burggraaff,2 Marcel Nijland,1,2,3 Sanne H. Tonino,1,2 Anne I.J. Arens,10 Roelf Valkema,11 Harm van Tinteren,12 Marta Lopez-Yurda,12 Arjan Diepstra,1,13 Daphne De Jong,2,14 and Anton Hagenbeek1,2

1Department of Hematology, Amsterdam UMC, University of Amsterdam, LYM MCCARE (Lymphoma and Myeloma Center Amsterdam), Cancer Center Amsterdam, Amsterdam, the Netherlands; 2HOVON and Lugenbump Lymphoma Phase I/II Consortium (LLPC), the Netherlands; 3Department of Hematology, Amsterdam UMC Vrije Univesiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands; 4Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; 5Department of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands; 6Department of Hematology, Hospital Saint Louis, Paris, France; 7Department of Hematology, Rigshospitalet, Copenhagen, Denmark; 8Department of Hematology, Centre Hospitalier Universitaire, Nantes, France; 9Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; 10Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands; 11Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands; 12Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands and 13Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands; HOVON Pathology Facility and Biobank, Amsterdam, the Netherlands

*MJK and JD contributed equally as co-first authors.

ABSTRACT

Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem cell transplant (auto-PBSCST) predicts progression-free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP (dexamethasone, high-dose cytarabine, cisplatin) to improve the mCR rate. In a phase I dose-escalation part of the study in 12 patients, we showed that BV-DHAP is feasible. This phase II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP (dexamethasone 40 mg days 1-4, cisplatin 100 mg/m² day 1 and cytarabine 2x2 g/m² day 2). Patients with a metabolic partial response (mPR) or mCR proceeded to HDC/auto-PBSCST. Based on independent central [18F]fluorodeoxyglucose (FDG) - positron emission tomography (PET) - computed tomography (CT) scan review, 42 of 52 evaluable patients (81% [95%CI: 67-90]) achieved an mCR before HDC/auto-PBSCST; five had an mPR and five had progressive disease (3 were not evaluable). After HDC/auto-PBSCST, four patients with an mPR converted to an mCR. Two-year PFS was 74% [95%CI: 63-86] and overall survival 95% [95%CI: 90-100]. Toxicity was manageable and mainly consisted of grade 3/4 hematologic toxicity, fever, nephrotoxicity, ototoxicity (grade 1/2), and transiently elevated liver enzymes during BV-DHAP. Eighteen patients developed new onset peripheral neuropathy (maximum grade 1/2); all recovered. In conclusion, BV-DHAP is a very effective salvage regimen in R/R cHL patients, but patients should be monitored closely for toxicity. (clinicaltrials.gov identifier: NCT02280993).